Start-Ups Swimming ...
Health Care: Drugs
Theravance Inc. (THRX: NASDAQ)
$36.24 -0.54 | -1.47%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -18.54M | -115.34M | -83.86M | -85.30M |
| Operating Gains/Losses | 187.00K | 0.00 | 33.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -841.00K | -29.00K | -448.00K | 2.76M |
| (Increase) Decrease in Inventories | -4.82M | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.48M | 3.31M | -236.00K | -2.70M |
| (Decrease) Increase In Other Current Liabilities | -1.83M | 5.12M | 3.32M | -2.62M |
| (Increase) Decrease In Other Working Capital | -131.30M | -16.20M | -20.48M | 4.27M |
| Other Non-Cash Items | 23.78M | 24.93M | 19.02M | 19.99M |
| Net Cash From Continuing Operations | -127.95M | -88.34M | -75.14M | -58.06M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -127.95M | -88.34M | -75.14M | -58.06M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 12.00K | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 274.63M | 248.80M | 143.88M | 123.06M |
| Purchases of Property, Plant & Equipment | -2.59M | -3.63M | -861.00K | -744.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -330.48M | -301.56M | -183.90M | -123.46M |
| Other Cash from Investing Activities | 60.00K | 715.00K | 557.00K | 2.88M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -58.28M | -55.82M | -40.31M | 1.74M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 0.00 | 25.81M | 231.43M | 11.72M |
| Repayment of Long-Term Debt | -69.00K | -206.00K | -184.00K | -131.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 236.38M | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 236.31M | 25.60M | 231.24M | 11.59M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 50.07M | -118.56M | 115.79M | -44.74M |
Portfolios with THRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorEarnings Short Squeeze Play...
- ProSeth Klarman - Baupost Group
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Usernew
Latest THRX Headlines from TheStreet
- 3 Stocks Pushing The Drugs Industry Higher 04.15.13 | 01:04 pm
- 5 Stocks Poised to Pop on Bullish Earnings 02.11.13 | 12:02 pm
- Insiders Trading THRX KSS TUES ELGX 11.06.12 | 10:11 am
- Theravance And Merck Sign Cardiovascular Disease Collaboration 10.16.12 | 08:10 am
- Theravance And Alfa Wassermann Enter Into Agreement To Develop And Commercialize Velusetrag For Gastroparesis 10.02.12 | 04:10 pm
- GSK And Theravance Announce FDA Acceptance Of FF/VI New Drug Application (NDA) Submission In The US For COPD 09.26.12 | 04:09 am
- Theravance's Management Presents At INC At Morgan Stanley Healthcare Conference (Transcript) 09.12.12 | 02:09 pm
- Theravance To Present At The Morgan Stanley Global Healthcare Conference 08.29.12 | 04:08 pm
- GSK And Theravance Announce Completion Of The Phase III Programme For Once-Daily LAMA/LABA (UMEC/VI) In COPD 08.24.12 | 07:08 am
- Theravance Inc. Stock Downgraded (THRX) 08.02.12 | 05:08 am
Press Releases for THRX
- BREOâ¿¢ ELLIPTAâ¿¢ Gains US Approval For The Treatment Of COPD - PR Newswire 05.10.13 | 04:05 pm
- FDA Advisory Committee Recommends Approval Of BREOâ¿¢ ELLIPTAâ¿¢ For The Treatment Of COPD - PR Newswire 04.17.13 | 05:04 pm
Partner Headlines for THRX
- Morning Market Movers - Benzinga 04.15.13 | 09:04 am
- Pipeline Progress at Theravance - Analyst Blog - Zacks 12.05.12 | 09:12 am
- Glaxo Invests in Nigeria - Analyst Blog - Zacks 11.28.12 | 09:11 am
- For NovaBay, Simplicity Is The Father Of Invention - Seeking Alpha 11.12.12 | 09:11 am
- Loss at THRX Narrower Than Expected - Analyst Blog - Zacks 10.31.12 | 09:10 am
- Glaxo Aims to Expand Synflorix Label - Analyst Blog - NASDAQ 09.19.12 | 03:09 pm
- Glaxo Increases Stake in RGDX - Analyst Blog - NASDAQ 09.18.12 | 09:09 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- Pipeline Advances at Glaxo/THRX - Analyst Blog - NASDAQ 08.27.12 | 08:08 pm
- Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX - GuruFocus 08.13.12 | 08:08 pm
